Replies to post #116468 on Biotech Values

[dav1234]

Moreover, NVS/MNTA may not even need to consider an at-risk launch; if NVS/MNTA get FDA approval before the Copaxone trial has run its course, I expect the parties to settle the patent litigation out of court.

sounds reasonable, we will find out if/when the approval is announced.,

In your opinion, is it plausible that the FDA is waiting for clarity on patent issue before issuing a decision on MCopax or would that normally not have any bearing on their review?